The industry group representing generic and biosimilar manufacturers has issued a new report that claims that Ireland’s policies are keeping the nation from benefitting from €25 million (approximately $29 million) in annual savings to its national health system.
While the European experience with biosimilars is often hailed as a model that the United States could benefit from following, some EU member states continue to grapple with policy barriers that limit biosimilar uptake. Medicines for Ireland, an industry group representing generic and biosimilar manufacturers, has issued a new report that claims that Ireland’s policies are keeping the nation from benefitting from €25 million (approximately $29 million) in annual savings to its national health system.
The report claims that as of January 2018, biosimilars had an approximate 2% market share for biologic therapies in Ireland, despite the fact that, as of the report’s date, 38 biosimilar products are approved for use in the European Union. Among the products with the lowest market share are biosimilar etanercept, with 1% of the market, and biosimilar insulin glargine, with just 0.2% of the market.
According to Medicines for Ireland, the Irish government must enact key policy measures if the uptake of biosimilars is to improve. In addition to such familiar suggestions as undertaking an awareness campaign to educate patients and providers about biosimilar therapies, the report calls for financial incentives to encourage biosimilar prescribing, particularly at the hospital level: gainsharing would allow hospitals to undertake switches to biosimilar drugs and retain a portion of the savings achieved, and quotas, which would set targets for biosimilar prescribing, would be beneficial in “creating a culture of cost consideration.”
Additionally, Medicines for Ireland suggests doing away with Ireland’s current mandatory price reductions for branded products when competitors enter the marketplace; currently, under a national agreement with the Irish Pharmaceutical Healthcare Association, when a generic or biosimilar drug is launched, the innovator product’s price must be discounted by 30%. Eliminating this mandated price drop could spur greater competition among new market entrants, the report states.
Finally, the report took aim at the national government, which has not yet delivered its promised National Biosimilar Policy. In August 2017, the nation’s Minister for Health published a consultation paper, with an open comment period, on the development of a new approach to biosimilars.
The paper put forth a variety of policy options, including prescribing biosimilars to new patients, switching stable patients to biosimilars, undertaking educational programs, implementing tendering programs, setting reference pricing guidelines, and limiting drug companies’ interactions with educational institutions or physicians. Medicines for Ireland’s report calls on the government to enact the new national policy in a timely way to allow for a more coherent approach to these therapies.
“With affordability now a key concern in respect of ensuring Irish patients have access to the medicines they need when they need them most,” said Owen McKeon, chairperson of Medicines for Ireland in an accompanying statement, “the Department of Health, Government, and wider medical community cannot afford to continue to ignore opportunities for further savings.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.